BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November

Day

• 1
• 2
• 3

• Press Releases

  Moleculent Introduces Glimt, the First Automated Instrument for Functional Profiling of Cell-Cell Interactions in Human Tissue

  November 3, 2026

   · 

  2 min read
• Press Releases

  Strand Therapeutics to Present Updated STX-001 Clinical Data Highlighting Durable, Systemic Anti-Tumor Activity, and Showcase STX-003 Trial Design at SITC 2026

  November 3, 2026

   · 

  3 min read
• Press Releases

  New SPIRARE II Data at TCT 2026 Show Restoring Normal Pulmonary Pressure Using Vertex™ System Tracked with Right Heart Recovery in Pulmonary Embolism

  November 3, 2026

   · 

  5 min read
• Press Releases

  Scholar Rock to Present at Upcoming November 2026 Investor Conferences

  November 3, 2026

   · 

  2 min read
• Press Releases

  Eureka Therapeutics Appoints Surgical Oncologist Dr. Jennifer F. Tseng to Scientific Advisory Board

  November 3, 2026

   · 

  2 min read
• Press Releases

  Stoke Therapeutics to Present at Upcoming Investor Conferences in November 2026

  November 3, 2026

   · 

  2 min read
• 

  Rare diseases

  Neurocrine defends Prader-Willi drug after another patient death

  Neurocrine Biosciences will conduct a new study for the rare disease drug Vykat to explore dosing and safety in patients with Prader-Willi syndrome who have complex health issues.

  November 3, 2026

   · 

  3 min read

   · 

  Annalee Armstrong
• 

  Deals

  Novartis puts $772M BioArctic deal on ice, skates away from brain-delivery alliance

  Novartis is discontinuing a neurodegeneration alliance with BioArctic in which the companies aimed to develop a drug candidate that could cross the blood-brain barrier.

  November 3, 2026

   · 

  1 min read

   · 

  Gabrielle Masson
• Press Releases

  Alnylam to Present Five-Year HELIOS-B Data and Expanding Evidence on the Benefits of RNAi-Powered TTR Silencing with AMVUTTRA® (vutrisiran) at AHA and ISA 2026

  November 3, 2026

   · 

  11 min read
• 

  Manufacturing

  Lonza agrees to buy 5 Merck KGaA facilities to accelerate US expansion

  The Swiss contract development and manufacturing organization will more than double its U.S. footprint by acquiring the Merck KGaA plants.

  November 3, 2026

   · 

  2 min read

   · 

  Nick Paul Taylor